中文
About Us
Corporate Overview
Management Team
Board of Directors
Our Science
Anti-viral Platform
RNA Interference
Fatty Liver Disease
Products & Pipline
Overview
HCV
HBV
ASC09
ASC06
Partnership
Investors
Financials & Filing
News
2020
2019
2018
2017
2016
2015
2014
Careers
2020
2019
2018
2017
2016
2015
2014
Ascletis’ NDA for Its All-oral HCV Treatment Accepted by CFDA
2018-08-06
Ascletis Filed NDA for Its All-oral HCV Treatment
2018-07-31
Ganovo® Phase III Clinical Study Won the Top Award at the Infectious Disease National Congress of Chinese Medical Association
2018-07-30
Ascletis and CR Pharmaceutical Commercial Group Co., Ltd. Signed Strategic Cooperation Agreement
2018-06-26
Ascletis Receives NDA Approval from China FDA for Ganovo
2018-06-13
1
2
»
